Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EPS (Weighted Average and Diluted) (2023 - 2024)

Contineum Therapeutics has reported EPS (Weighted Average and Diluted) over the past 2 years, most recently at -$0.57 for Q4 2024.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.57 for Q4 2024, down 62.86% from a year ago — trailing twelve months through Dec 2024 was -$1.71 (changed N/A YoY), and the annual figure for FY2025 was -$2.17, changed 0.46%.
  • EPS (Weighted Average and Diluted) for Q4 2024 was -$0.57 at Contineum Therapeutics, down from -$0.4 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for CTNM hit a ceiling of $0.84 in Q2 2023 and a floor of -$2.69 in Q3 2023.